NCT05765006View on ClinicalTrials.gov

CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

Relma-cel

CD19-targeted Chimeric AntigenReceptor (CAR) T Cells; Relma-cel be administrated at four dose level:25×106 CAR+ T cells、50×106 CAR+ T cells、100×106 CAR+ T cells/150×106 CAR+ T cells

Trial Locations (1)

Unknown

RECRUITING

Relma-cel Medical, Shanghai

All Listed Sponsors
lead

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY